Shares of Cleveland BioLabs got an 8% bounce on 10 September on word the US FDA was in agreement with the firm's proposed pivotal animal efficacy studies for Entolimod (CBLB502) as a radiation countermeasure and also accepted the company’s recently concluded good laboratory practice non-human primate study as part of the pivotal program.
Shares of the Buffalo, New York-based biotech closed at $2.07 on 10 September, a gain of 4%, or 8 cents.